PubHawk
May 2021 PMID 33676782

Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment.

Jerome Custers, Denny Kim, Maarten Leyssen, Marc Gurwith, Frank Tomaka, James Robertson, Esther Heijnen, Richard Condit, Georgi Shukarev, Dirk Heerwegh, Roy van Heesbeen, Hanneke Schuitemaker, Macaya Douoguih, Eric Evans, Emily R Smith

Download social card

Mentions

30
Peak: 6 in Jul 2021
across 4 sources since Oct 2020

Extended reach

61,076
potential audience

Total likes

138

Video views

6,966

Mentions per month

Oct 2020 – Sep 2024

Where it's discussed

  • X / Twitter21 posts
  • News6 articles
  • YouTube2 videos
  • Facebook1 posts

AI synopsis

What people are saying

The discussions reveal a generally supportive attitude, with some users emphasizing their familiarity with the topic by citing technical sources or clarifying misconceptions, such as correcting misunderstandings about gene deletion. The tone varies from cautious skepticism to informative reassurance, reflecting a balanced engagement with both scientific accuracy and public concern.

AgreementModerate agreement

Most discussions show support and trust in the publication’s findings about Ad26 vectors, with some emphasizing its safety profiles.

InterestModerate interest

Participants demonstrate moderate curiosity, often referencing specific details about adenovirus vectors and their implications.

EngagementModerate engagement

Posts frequently analyze technical details, debunk misconceptions, or cite sources, indicating active involvement.

ImpactModerate impact

The debates could influence perceptions around the vaccine technology and safety, possibly affecting public trust or scientific understanding.

Abstract in brief

  • Replication-incompetent Ad26 viral vectors are being explored for vaccine development because they can safely deliver transgenes without replicating within the host, and they are manufactured efficiently at scale using mammalian cell lines.
  • These Ad26-based vaccines have been extensively tested in clinical trials involving over 114,000 participants, showing good safety profiles with no major safety concerns, and they induce strong and durable immune responses, both humoral (antibody) and cellular.
  • Despite preexisting immunity to Ad26 in some individuals, studies indicate it does not significantly affect the vaccine’s ability to generate an immune response, with ongoing evaluations to confirm their safety and effectiveness, including the approval of the first Ad26-based Ebola vaccine.
Read the full abstract

Top posts

Most liked on X and Bluesky
นายท่านหมีป่า โรงงานปั๊มเปเปอร์
@Ake_DrMEE · X

10.1016/ S0140-6736(20)31866-3, 10.1371/journal.pone.0040385, 10.1016/ S0140-6736(20)31604-4, 10.1089/10430340460745838, 10.1128/JVI.02055-12, 10.1016/j.vaccine.2020.09.018, 10.1128/JVI.02058-12 #ถ้าผู้นำตายเราจะรอดกันหมด #รัฐบาลส้นตีน #รัฐบาลขยะ #Novavax #ซิโนแวคคือการคอรัปชั่น

Jul 13, 2021 · 3 likes · 5 shares · 10,398 followers View post →
Darren Schmidt, D.C.
@realfoodcures · X

#10 Adenoviruses used in both the Johnson & Johnson shot and the AstraZeneca shots pose a risk of cancer. https://t.co/HfCCLPND8s https://t.co/qf1HBBmpxF https://t.co/vnpeW964ql https://t.co/DjUaJAc7Yg

May 22, 2021 · 3 likes · 1 share · 5,827 followers View post →
D.S. Nelson
@process_x · X

@keesaroo @WellLahTeeFuKin @FaithInJesus1st @swhotmess @lonestarangle @painadvocateAR @2Spaceninja15 @Anonylyzer13 @InAMadWorld111 @Jesusis53688620 @Jesussaves_77 @AndersJonita @haterdeep2 This woman is either fear-mongering or doesn't know what she's talking about. Patent: https://t.co/gI5IHLlSR8 She claims the patent says it deletes the E1 gene in HUMANS. It doesn't. This is referring to the E1 gene in the adenovirus vector. See: https://t.co/MxFowGyPzq

Nov 18, 2021 · 3 likes · 5,715 followers View post →
A$AP mAbs
@ImmunoGangsta · X

@DopplerEffect93 @SaltaoVladimir @ENirenberg @weldeiry @Debunk_the_Funk @DravenS17 @Jikkyleaks @gorskon Tell me, is process DNA present under regulatory limits still a contaminant? "Won't do anything", "anti-vax scheme"... now you are just babbling. See: https://t.co/iZAf3ErGHz It is what the J&J folk base their risk analysis on here: https://t.co/9m2gr8wUft

Oct 14, 2023 · 3 likes · 2,038 followers View post →
IDI-UCV
@IdiUcv · X

Vacunas basadas en vectores virales Ad26 incompetentes para la replicación: plantilla estandarizada con consideraciones clave para una evaluación de riesgo / beneficio. https://t.co/299pAyCqQz https://t.co/xapyCQnMAF

Oct 3, 2020 · 2 likes · 4 shares · 2,949 followers View post →
Javi Ciborro
@papayaykware · X

Los adenovirus y el riesgo de cáncer La inyección actualmente autorizada por Johnson and Johnson está hecha con la cáscara Ad26.COV-2.S, un adenovirus humano aislado por primera vez en 1956 a partir de una muestra anal obtenida de un bebé varón de 9 meses https://t.co/UvPBhtRqrS

May 9, 2021 · 1 like · 8,027 followers View post →

All mentions

Atomsk's Sanakan
@AtomsksSanakan · X

@ImmunoGangsta @tenebra99 @syrupfrogger @Rosewind2007 If you're going to discuss Ad26, then cite sources on Ad26. Don't cite sources on Ad5 and then act like it applies to Ad26, because you were incompetently confused them. https://t.co/Sy3ajchYKu https://t.co/G5GUDIPmuL https://t.co/t9jn0Q7SE6

Sep 29, 2024 · 3,357 followers View post →
A$AP mAbs
@ImmunoGangsta · X

@DopplerEffect93 @SaltaoVladimir @ENirenberg @weldeiry @Debunk_the_Funk @DravenS17 @Jikkyleaks @gorskon Tell me, is process DNA present under regulatory limits still a contaminant? "Won't do anything", "anti-vax scheme"... now you are just babbling. See: https://t.co/iZAf3ErGHz It is what the J&J folk base their risk analysis on here: https://t.co/9m2gr8wUft

Oct 14, 2023 · 3 likes · 2,038 followers View post →
Roy v Heesbeen
@rvh15374957 · X

@mholkers Dit artikel is wel een aardige samenvatting over Ad26 (wel enigszins outdated) https://t.co/I5vryOou7A

Jan 9, 2022 · 453 followers View post →
D.S. Nelson
@process_x · X

@Jesussaves_77 @keesaroo @WellLahTeeFuKin @FaithInJesus1st @swhotmess @lonestarangle @painadvocateAR @2Spaceninja15 @Anonylyzer13 @InAMadWorld111 @Jesusis53688620 @AndersJonita @haterdeep2 It's E1 in the vector that's deleted, which I assume you'd want. "Replication-incompetent adenoviral vectors have been under investigation as a platform to carry a variety of transgenes, and express them as a basis for vaccine development." https://t.co/MxFowGyPzq

Nov 18, 2021 · 5,715 followers View post →
D.S. Nelson
@process_x · X

@keesaroo @WellLahTeeFuKin @FaithInJesus1st @swhotmess @lonestarangle @painadvocateAR @2Spaceninja15 @Anonylyzer13 @InAMadWorld111 @Jesusis53688620 @Jesussaves_77 @AndersJonita @haterdeep2 This woman is either fear-mongering or doesn't know what she's talking about. Patent: https://t.co/gI5IHLlSR8 She claims the patent says it deletes the E1 gene in HUMANS. It doesn't. This is referring to the E1 gene in the adenovirus vector. See: https://t.co/MxFowGyPzq

Nov 18, 2021 · 3 likes · 5,715 followers View post →
Adriaan W
@JansensAdriaan · X

@sn0rx https://t.co/Gg1vMeYDdb

Nov 15, 2021 · 1 like · 3,827 followers View post →
CyberWizard
@CyberWiz_YT · X

https://t.co/8LzlslVhke

Sep 11, 2021 · 286 followers View post →
cherry_burl
@cherry_burl · X

RT @Ake_DrMEE: 10.1016/ S0140-6736(20)31866-3, 10.1371/journal.pone.0040385, 10.1016/ S0140-6736(20)31604-4, 10.1089/10430340460745838, 10.…

Jul 15, 2021 · 5 shares · 203 followers View post →
axn ◡̈
@seyaxn · X

RT @Ake_DrMEE: 10.1016/ S0140-6736(20)31866-3, 10.1371/journal.pone.0040385, 10.1016/ S0140-6736(20)31604-4, 10.1089/10430340460745838, 10.…

Jul 14, 2021 · 5 shares · 104 followers View post →
ペンギン
@NatGTNat · X

RT @Ake_DrMEE: 10.1016/ S0140-6736(20)31866-3, 10.1371/journal.pone.0040385, 10.1016/ S0140-6736(20)31604-4, 10.1089/10430340460745838, 10.…

Jul 13, 2021 · 5 shares · 223 followers View post →
ปุ้ม ละอองกอ
@sabjustsab · X

RT @Ake_DrMEE: 10.1016/ S0140-6736(20)31866-3, 10.1371/journal.pone.0040385, 10.1016/ S0140-6736(20)31604-4, 10.1089/10430340460745838, 10.…

Jul 13, 2021 · 5 shares · 244 followers View post →
MelonMoMo97
@momokumata · X

RT @Ake_DrMEE: 10.1016/ S0140-6736(20)31866-3, 10.1371/journal.pone.0040385, 10.1016/ S0140-6736(20)31604-4, 10.1089/10430340460745838, 10.…

Jul 13, 2021 · 5 shares · 307 followers View post →
นายท่านหมีป่า โรงงานปั๊มเปเปอร์
@Ake_DrMEE · X

10.1016/ S0140-6736(20)31866-3, 10.1371/journal.pone.0040385, 10.1016/ S0140-6736(20)31604-4, 10.1089/10430340460745838, 10.1128/JVI.02055-12, 10.1016/j.vaccine.2020.09.018, 10.1128/JVI.02058-12 #ถ้าผู้นำตายเราจะรอดกันหมด #รัฐบาลส้นตีน #รัฐบาลขยะ #Novavax #ซิโนแวคคือการคอรัปชั่น

Jul 13, 2021 · 3 likes · 5 shares · 10,398 followers View post →
Life Under The Microscope
@LifeUnderTheMic · X

RT @realfoodcures: #10 Adenoviruses used in both the Johnson & Johnson shot and the AstraZeneca shots pose a risk of cancer. https://t.co/H…

May 22, 2021 · 1 share · 213 followers View post →
Darren Schmidt, D.C.
@realfoodcures · X

#10 Adenoviruses used in both the Johnson & Johnson shot and the AstraZeneca shots pose a risk of cancer. https://t.co/HfCCLPND8s https://t.co/qf1HBBmpxF https://t.co/vnpeW964ql https://t.co/DjUaJAc7Yg

May 22, 2021 · 3 likes · 1 share · 5,827 followers View post →
Javi Ciborro
@papayaykware · X

Los adenovirus y el riesgo de cáncer La inyección actualmente autorizada por Johnson and Johnson está hecha con la cáscara Ad26.COV-2.S, un adenovirus humano aislado por primera vez en 1956 a partir de una muestra anal obtenida de un bebé varón de 9 meses https://t.co/UvPBhtRqrS

May 9, 2021 · 1 like · 8,027 followers View post →
bmi32
@bmi32 · X

https://t.co/qyoXmkIL0C Vaccines based on replication incompetent Ad26 viral vectors: Standardized template with key considerations for a risk/benefit assessment

Feb 6, 2021 · 116 followers View post →
Juan B. De Sanctis
@DesanctisJuan · X

RT @IdiUcv: Vacunas basadas en vectores virales Ad26 incompetentes para la replicación: plantilla estandarizada con consideraciones clave p…

Oct 4, 2020 · 4 shares · 316 followers View post →
IDI-UCV
@IdiUcv · X

RT @IdiUcv: Vacunas basadas en vectores virales Ad26 incompetentes para la replicación: plantilla estandarizada con consideraciones clave p…

Oct 4, 2020 · 4 shares · 2,949 followers View post →
Yalalu. America Lupi
@yalalu · X

RT @IdiUcv: Vacunas basadas en vectores virales Ad26 incompetentes para la replicación: plantilla estandarizada con consideraciones clave p…

Oct 3, 2020 · 4 shares · 678 followers View post →
IDI-UCV
@IdiUcv · X

Vacunas basadas en vectores virales Ad26 incompetentes para la replicación: plantilla estandarizada con consideraciones clave para una evaluación de riesgo / beneficio. https://t.co/299pAyCqQz https://t.co/xapyCQnMAF

Oct 3, 2020 · 2 likes · 4 shares · 2,949 followers View post →
In situ structural analysis of SARS-CoV-2 spike reveals flexibility ...
News

10.1016/j.cell.2020.09.018 · Web of Science · Google Scholar. a [...] with the ... https://doi.org/10.1016/j.vaccine.2025.127404 · Crossref. Andrea Mussini ...

Dec 14, 2025 View →
Analyzing the Antiviral Activity of Graphene Oxide Against COVID-19
News

doi.org/10.1016/j.bbrc.2020.09.018. Joshi, S. R., et al. (2020) Low ... doi.org/10.1016/j.vaccine.2006.08.011. Kedambaimoole, V., et al ...

Dec 16, 2021 View →
Saliva, Nasal Swabs, or Blood: Best Samples for Pathogen Detection
News

... vaccines.2 Most tests are used for the qualitative detection of ... doi:10.1016/j.cca.2020.09.018. 7. MacMullan MA, Ibrayeva A, Trettner ...

Nov 22, 2021 View →
New Study Shows Most Blood Cancer Patients Benefit from an ...
News

... vaccine despite having no detectable ... doi.org/10.1016/j.ccell.2020.09.018. 2 Vijenthera A, Gong IY, Fox TA ...

Sep 13, 2021 View →
Structural impact on SARS-CoV-2 spike protein by D614G substitution
News

These findings extend our understanding of viral entry and suggest an improved immunogen for vaccine development. ... doi:10.1016/j.cell.2020.09.

Mar 16, 2021 View →
Hello everyone. I was having a debate with someone over the ...
Facebook

... vaccine, as did uncounted people later on… Only one thing is ... https://doi.org/10.1016/j.cell. 2020.09.018. linkinghub.elsevier.com.

Jan 14, 2021 View →
As 2020 ends, here's what we still don't know about COVID-19 ...
News

... vaccine on December 2 and the United States poised to follow suit ... doi: 10.1016/j.cell.2020.09.018. H. Xia et al. Evasion of Type I ...

Dec 9, 2020 View →